版本:
中国

BRIEF-Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

March 7 Glenmark Pharmaceuticals Ltd:

* Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304

* Plans to initiate clinical development with a Phase 2 study of GSP 304 in subjects with mild to moderate COPD Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐